Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy

Research output: Contribution to journalArticle

Abstract

Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment in selected adult cases of severe CIDPs. We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP.

Original languageEnglish
Pages (from-to)301-303
Number of pages3
JournalEuropean Journal of Paediatric Neurology
Volume16
Issue number3
DOIs
Publication statusPublished - May 2012

Keywords

  • CIPD
  • Polineuropathy
  • Rituximab

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy'. Together they form a unique fingerprint.

  • Cite this